PubMed · 15977424
Technology evaluation: HspE7 (Stressgen).
Abstract
Stressgen is developing HspE7, a recombinant fusion protein comprising the human papillomavirus (HPV) E7 antigen and the heat shock protein Hsp65 from Mycobacterium bovis, as a potential therapy for conditions associated with HPV infection. This therapy is currently undergoing phase III clinical trials.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Paulo Cesar Maciag, Yvonne Paterson. 2005. Technology evaluation: HspE7 (Stressgen).. https://pubmed.ncbi.nlm.nih.gov/15977424/
Cite the original work for its findings. Save a collection to share your selection of sources.